China’s CBIRC has quietly made a big correction in Tesla’s August Model Y insured sales which eliminated the huge discrepancy between results previously reported by CATARC and sales numbers from CPCA.
August Model 3 sales? Still bad, and so is the specter of Tesla’s shrinking market share in the largest EV market in the world.
CATARC data for insured August sales was recently amended by CBIRC to indicate Tesla Motors (TSLA US) Model Y sales actually closely tracked reported sales by CPCA—which is more typical with long term trends.
As such, this report updates my previous report Tesla’s August Sales Numbers in China Don’t Add Up published on 9/17/21 to reflect the corrected numbers from CBIRC versus the grossly incorrect data previously reported by CATARC.
Well, That’s Completely Different
China Automotive Technology and Research Center CATARC tracks insurance registrations rather than sales data provided by carmakers as collected by CPCA. This tends to align closely with monthly retail sales since cars must be insured before they can be licensed. Tesla sales are all cash due upon delivery, so insurance must be arranged and finalized before the customer can take possession of the car.
CATARC is regulated by China Banking & Insurance Regulatory Commission (CBIRC).
Important data from CBIRC was recently released since my report Tesla’s August Sales Numbers in China Don’t Add Up was published on 9/17/21 which corrected an extreme and highly unusual difference between reported August sales by CPCA and insured sales reported by CATARC.
CBIRC reported, without further clarification, that indicated Model Y insured sales were 11,721 in August—well within the more traditionally slim margin versus CPCA reported sales at 11,576.
This corrected a dramatically lower 1,538 for Model Y, down 28% versus weak July results, which previously had been reported by CATARC and which had created a stunning 10,038 difference versus the 11,576 previously reported by CPCA.
CBIRC reported Model 3 insured August sales at 1,273, confirming previously reported results by CATARC which had closely aligned with the weak 1,309 (down a whopping 89% y/y) as reported by CPCA.
CBIRC’s action to correct the large discrepancy in reported August Model Y sales was no doubt a great relief to Tesla, which has enough trouble with regulators already in China as well as the US—not to mention its voracious local rivals which are rapidly absorbing market share.
Originally Posted on October 15, 2021 – Tesla: Now That’s More Like It
Smartkarma posts and insights are provided for informational purposes only and shall not be construed as or relied upon in any circumstances as professional, targeted financial or investment advice or be considered to form part of any offer for sale, subscription, solicitation or invitation to buy or subscribe for any securities or financial products. Views expressed in third-party articles are those of the authors and do not necessarily represent the views or opinion of Smartkarma.
Disclosure: Interactive Brokers
Information posted on IBKR Traders’ Insight that is provided by third-parties and not by Interactive Brokers does NOT constitute a recommendation by Interactive Brokers that you should contract for the services of that third party. Third-party participants who contribute to IBKR Traders’ Insight are independent of Interactive Brokers and Interactive Brokers does not make any representations or warranties concerning the services offered, their past or future performance, or the accuracy of the information provided by the third party. Past performance is no guarantee of future results.
This material is from Smartkarma and is being posted with permission from Smartkarma. The views expressed in this material are solely those of the author and/or Smartkarma and IBKR is not endorsing or recommending any investment or trading discussed in the material. This material is not and should not be construed as an offer to sell or the solicitation of an offer to buy any security. To the extent that this material discusses general market activity, industry or sector trends or other broad based economic or political conditions, it should not be construed as research or investment advice. To the extent that it includes references to specific securities, commodities, currencies, or other instruments, those references do not constitute a recommendation to buy, sell or hold such security. This material does not and is not intended to take into account the particular financial conditions, investment objectives or requirements of individual customers. Before acting on this material, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.
In accordance with EU regulation: The statements in this document shall not be considered as an objective or independent explanation of the matters. Please note that this document (a) has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and (b) is not subject to any prohibition on dealing ahead of the dissemination or publication of investment research.
Any trading symbols displayed are for illustrative purposes only and are not intended to portray recommendations.